Drotin-M Safety in Breastfeeding
Mefenamic acid (one component of Drotin-M) should be used with extreme caution during breastfeeding and is generally not recommended, as trace amounts are present in breast milk and the FDA label specifically states that a decision should be made whether to discontinue nursing or discontinue the drug due to potential for serious adverse reactions in nursing infants. 1
Understanding Drotin-M Components
Drotin-M is a combination medication containing:
- Drotaverine (antispasmodic)
- Mefenamic acid (NSAID)
Unfortunately, there is no specific evidence available for drotaverine safety in breastfeeding from the provided sources. However, we have clear guidance on mefenamic acid.
Evidence for Mefenamic Acid in Breastfeeding
FDA Drug Label Guidance (Highest Priority)
The FDA label for mefenamic acid explicitly states: "Trace amounts of mefenamic acid may be present in breast milk and transmitted to the nursing infant. Because of the potential for serious adverse reactions in nursing infants from mefenamic acid, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother." 1
This is a cautionary stance that does not provide reassurance for routine use during breastfeeding.
Guideline Evidence on NSAIDs in Breastfeeding
While the 2020 Association of Anaesthetists guideline addresses several NSAIDs as compatible with breastfeeding (ibuprofen, diclofenac, naproxen, ketorolac), mefenamic acid is notably absent from their list of recommended NSAIDs 2. This omission is significant given that the guideline specifically addresses analgesic safety in breastfeeding.
The 2009 American Family Physician guideline on NSAID prescribing states that "The American Academy of Pediatrics considers ibuprofen, indomethacin, and naproxen safe in breastfeeding women" but does not include mefenamic acid in this safe list 3.
Research Evidence
A 2003 review on antibiotic and analgesic use during lactation recommends paracetamol, low-dose aspirin, and short-term NSAIDs as compatible with breastfeeding but does not specifically endorse mefenamic acid 4.
Clinical Algorithm for Decision-Making
When a breastfeeding mother requires pain/spasm relief:
First-line alternatives (safer options):
If Drotin-M is being considered:
- Assess whether the antispasmodic component (drotaverine) is truly necessary
- Consider alternative antispasmodics with better lactation data
- Evaluate if pain control alone with a safer NSAID would suffice
If no alternatives are suitable:
- Use the lowest effective dose for the shortest duration
- Monitor the infant closely for signs of:
- Drowsiness or lethargy
- Poor feeding
- Gastrointestinal symptoms
- Any unusual behavior
- Consider timing doses immediately after breastfeeding to minimize infant exposure
- Discuss with the mother the option of temporary interruption of breastfeeding if prolonged use is needed
Critical Caveats
- Neonates with jaundice: NSAIDs are contraindicated when breastfeeding a neonate with jaundice because most NSAIDs displace bilirubin 3
- Premature or ill infants: Exercise additional caution as drug clearance may be impaired
- Lack of drotaverine data: The absence of safety information for drotaverine in breastfeeding adds another layer of uncertainty to Drotin-M use
Bottom Line
Given the FDA's cautionary labeling for mefenamic acid, the absence of drotaverine safety data, and the availability of well-studied safer alternatives (ibuprofen, diclofenac, paracetamol), Drotin-M should not be considered a first-line or routine option for breastfeeding mothers. If absolutely necessary due to specific clinical circumstances, use the minimum effective dose for the shortest possible duration with close infant monitoring, but strongly consider switching to evidence-based safer alternatives.